Evidence map›Paper›PMID 39004714›Full record

ArticleBMC public health2024

Perception of couples' on multipurpose prevention technology attribute choice: the case of MTN 045.

Adlight Dandadzi, Alinda M Young, Petina Musara, Mary Kate Shapley-Quinn, Doreen Kemigisha, Prisca Mutero, Nyaradzo M Mgodi, Juliane Etima, Alexandra A Minnis

Abstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adlight DandadziUniversity of Zimbabwe-Clinical Trials Research Centre, Harare, Zimbabwe. adandadzi@uz-ctrc.org.ORCID 0000-0003-1162-6917
Alinda M YoungWomen's Global Health Imperative, RTI International, Berkeley, CA, USA.
Petina MusaraUniversity of Zimbabwe-Clinical Trials Research Centre, Harare, Zimbabwe.
Mary Kate Shapley-QuinnWomen's Global Health Imperative, RTI International, Berkeley, CA, USA.
Doreen KemigishaMakerere University-Johns Hopkins Research Collaboration, Kampala, Uganda.
Prisca MuteroUniversity of Zimbabwe-Clinical Trials Research Centre, Harare, Zimbabwe.
Nyaradzo M MgodiUniversity of Zimbabwe-Clinical Trials Research Centre, Harare, Zimbabwe.
Juliane EtimaMakerere University-Johns Hopkins Research Collaboration, Kampala, Uganda.
Alexandra A MinnisWomen's Global Health Imperative, RTI International, Berkeley, CA, USA.

Funding

SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

backgroundMultipurpose prevention technologies (MPTs) are products capable of simultaneously addressing multiple sexual and reproductive health needs such as unwanted pregnancy, STIs including HIV-1, and other reproductive tract infections. MPTs are urgently needed to address the double burden of unplanned pregnancy and HIV. While condoms are currently the only accessible MPTs, they are not solely under a woman's control, and female condoms face limitations due to poor acceptability and high cost.

methodsWe conducted a sub-analysis of qualitative data from 39 couples participating in the MTN 045 study to examine the perception of couples on choice and acceptability of a "2 in 1" MPT that combines HIV and pregnancy prevention.

resultsCouples recognized the benefits of MPTs for HIV and pregnancy prevention but perceptions tied to each indication and a novel prevention technology tool raised important concerns relevant to use of future MPTs. In the study, participants' perceptions of MPT use were influenced by pregnancy planning. When the timing was less critical, they prioritized HIV prevention. Misinformation about family planning methods, including MPTs, affected decision-making with potential to hinder uptake of future MPTs. Concerns about side effects, such as weight gain and hormonal imbalances, influenced willingness to use MPTs.

conclusionAddressing the myths and misconceptions surrounding the use of contraceptives is crucial in promoting their acceptance and ultimate use. Strategies for addressing the drawbacks women might experience while using a particular product should be in place as new MPTs progress through the development pipeline and approach roll-out.

Indexed as

HIV InfectionsAdultChoice BehaviorContraceptionFamily Planning ServicesFemaleHealth Knowledge, Attitudes, PracticeHumansMalePregnancyQualitative ResearchYoung AdultCouplesEastern and Southern AfricaHIVMultipurpose prevention technologyPregnancy

Identifiers

PMID39004714
PMCPMC11247780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.